3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Genitourinary
1
CNS
1
Conditions
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Neuroblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Carcinoma, Renal Cell
1
Interventions
ponatinib
4
fludarabine
4
Cyclophosphamide
3
fludarabine phosphate
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Imatinib Mesylate
2
Busulfan
2
Bone Marrow Transplantation
2
trametinib
1
tetulomab tetraxetan lu-177
1
ruxolitinib
1
pertuzumab
1
nirogacestat
1
nilotinib
1
gilteritinib
1
emvododstat
1
dabrafenib
1
bosutinib
1
blinatumomab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
alectinib
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled